Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 261 of 6351
-
Radiation plus immunotherapy may make inoperable liver cancer operable
Disease control Recruiting nowHepatocellular carcinoma (HCC) is one of the commonest cancers worldwide and ranks the third on the incidence of cancer-related death. There are more than 500000 new cases diagnosed annually worldwide. The incidence and prevalence of HCC are on rising trend with the majority of t…
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can mobile eye scans in villages prevent blindness in older adults?
Prevention Recruiting nowThe vast majority of blindness is avoidable. The World Health Organization (WHO) estimates that 80% of cases of visual impairment could be prevented or reversed with early diagnosis and treatment. The leading causes of visual impairment are cataract and refractive error, followed…
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Immunotherapy combo shows promise in bile duct cancer trial
Disease control OngoingDurvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1).
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Triple-Drug attack aims to wipe out mantle cell lymphoma
Disease control OngoingThis phase II trial studies how well bendamustine, obinutuzumab, and venetoclax work in treating patients with mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the c…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a targeted pill turn the tide against a bone marrow disorder?
Disease control Ongoingpatients with MDS (Myelodysplastic Syndrome) and mutated IDH2 patients will be treated with AG221 (IDH2 inhibitor)
Phase 2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for older AML patients: uproleselan combo trial shows promise
Disease control OngoingThis phase II/III trial studies how well daunorubicin and cytarabine with or without uproleselan works in treating older adult patients with acute myeloid leukemia receiving intensive induction chemotherapy. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Aggressive chemo schedule put to the test in brain cancer trial
Disease control OngoingDue to conflicting data on the optimal moment to start TMZ chemotherapy and the impact of prolongation of the adjuvant phase with TMZ, the ANOCEF (Association des Neuro-Oncologues d'Expression Francophone) group proposes this randomized trial comparing an intensified arm (early T…
Phase 3 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Could a targeted drug boost stem cell transplant success in lymphoma?
Disease control CompletedThe purpose of this study is to determine the correct dose and safety of adding a new cancer drug, Venetoclax, to a standard combination of chemotherapy drugs used prior to Autologous stem cell transplant (ASCT) in participants with Non-Hodgkin Lymphoma (NHL). In this study, Vene…
Phase 1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Off-the-Shelf CAR t cells take on tough lymphomas and leukemias
Disease control Recruiting nowThis is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.
Phase 1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Immunotherapy duo before liver surgery shows promise against cancer
Disease control CompletedThe PRIME-HCC trial will assess the effects of combination treatment with nivolumab (OPDIVO) and ipilimumab (YERVOY) pre-operatively in hepatocellular carcinoma patients for whom liver resection is planned. The trial will be conducted at a small number of National Health Service …
Phase 1/2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could timing of immunotherapy boost melanoma survival?
Disease control OngoingThis phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a tooth's own pulp be used to regenerate root canals?
Cure CancelledThe purpose of this study is to develop new improved therapy for teeth that require root canals due to tooth infection or tooth inflammation. Investigators will recruit total of 50 participants from the age group 7 - 50 at the UCLA School of Dentistry Endodontic clinic. The parti…
Sponsor: University of California, Los Angeles • Aim: Cure
Last updated Jul 25, 2026 00:00 UTC
-
Triple threat: new drug combo aims to beat CLL in younger patients
Disease control OngoingThis phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Obinutuzumab is a monoclo…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Herbal remedy vs. standard drug: a new hope for thalassemia iron overload?
Disease control CompletedThis research study was an experimental, randomized, controlled clinical trial to evaluate the safety and efficacy of coded Unani formulation Irochel for the management of IOL due to repetitive blood transfusion in comparison with DFO in already diagnosed 132 transfusion-dependen…
Phase 3 • Sponsor: Hamdard University • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for GIST patients: ripretinib takes on sunitinib in major trial
Disease control OngoingThis is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1…
Phase 3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Triple chemo attack shows promise against tough bile duct cancers
Disease control CompletedThis phase III trial studies how well gemcitabine hydrochloride and cisplatin given with or without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hy…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Engineered donor cells aim to beat blood cancer without severe side effects
Disease control OngoingPatients less than or equal to 21 years old with high-risk hematologic malignancies who would likely benefit from allogeneic hematopoietic cell transplantation (HCT). Patients with a suitable HLA matched sibling or unrelated donor identified will be eligible for participation ONL…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can targeted drug cocktails tame mesothelioma?
Disease control CompletedMiST is a British Lung Foundation funded, University of Leicester Study, a multi-arm stratified therapy based clinical trial for patients with relapsed mesothelioma. The goal of MiST is to enable acceleration of novel, effective personalised therapy as a basis for improving surv…
Phase 2 • Sponsor: University of Leicester • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New clamping method could save preterm brains
Disease control CompletedDelayed cord clamping (DCC) in preterm infants results in a decrease in mortality and a trend towards fewer intraventricular haemorrhages. However, preterm infants needing immediate interventions for stabilisation or resuscitation were generally clamped immediately and excluded f…
Sponsor: Leiden University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New cocktail shows promise against Tough-to-Treat colon cancer
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.
Phase 2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC